Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 3
2004 6
2005 2
2006 3
2007 4
2008 4
2009 4
2010 3
2011 6
2012 4
2013 8
2014 11
2015 12
2016 15
2017 12
2018 13
2019 15
2020 18
2021 19
2022 9
Text availability
Article attribute
Article type
Publication date

Search Results

149 results
Results by year
Filters applied: . Clear all
Page 1
Author Correction: High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer.
Palafox M, Monserrat L, Bellet M, Villacampa G, Gonzalez-Perez A, Oliveira M, Brasó-Maristany F, Ibrahimi N, Kannan S, Mina L, Herrera-Abreu MT, Òdena A, Sánchez-Guixé M, Capelán M, Azaro A, Bruna A, Rodríguez O, Guzmán M, Grueso J, Viaplana C, Hernández J, Su F, Lin K, Clarke RB, Caldas C, Arribas J, Michiels S, García-Sanz A, Turner NC, Prat A, Nuciforo P, Dienstmann R, Verma CS, Lopez-Bigas N, Scaltriti M, Arnedos M, Saura C, Serra V. Palafox M, et al. Among authors: scaltriti m. Nat Commun. 2022 Nov 14;13(1):6928. doi: 10.1038/s41467-022-34580-3. Nat Commun. 2022. PMID: 36376284 Free PMC article. No abstract available.
High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer.
Palafox M, Monserrat L, Bellet M, Villacampa G, Gonzalez-Perez A, Oliveira M, Brasó-Maristany F, Ibrahimi N, Kannan S, Mina L, Herrera-Abreu MT, Òdena A, Sánchez-Guixé M, Capelán M, Azaro A, Bruna A, Rodríguez O, Guzmán M, Grueso J, Viaplana C, Hernández J, Su F, Lin K, Clarke RB, Caldas C, Arribas J, Michiels S, García-Sanz A, Turner NC, Prat A, Nuciforo P, Dienstmann R, Verma CS, Lopez-Bigas N, Scaltriti M, Arnedos M, Saura C, Serra V. Palafox M, et al. Among authors: scaltriti m. Nat Commun. 2022 Sep 7;13(1):5258. doi: 10.1038/s41467-022-32828-6. Nat Commun. 2022. PMID: 36071033 Free PMC article.
Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study.
Brunelli M, Martignoni G, Malpeli G, Volpe A, Cima L, Raspollini MR, Barbareschi M, Tafuri A, Masi G, Barzon L, Ammendola S, Villanova M, Cerruto MA, Milella M, Buti S, Bersanelli M, Fornarini G, Rebuzzi SE, Vellone VG, Gaggero G, Procopio G, Verzoni E, Bracarda S, Fanelli M, Sabbatini R, Passalacqua R, Perrucci B, Giganti MO, Donini M, Panni S, Tucci M, Prati V, Ortega C, Caliò A, Eccher A, Alongi F, Pappagallo G, Iacovelli R, Mosca A, Umari P, Montagnani I, Gobbo S, Atzori F, Munari E, Maruzzo M, Basso U, Pierconti F, Patriarca C, Colombo P, Lapini A, Conti G, Salvioni R, Bollito E, Cossarizza A, Massari F, Rizzo M, Franco R, Zito-Marino F, Aberasturi Plata Y, Galuppini F, Sbaraglia M, Fassan M, Dei Tos AP, Colecchia M, Moch H, Scaltriti M, Porta C, Delahunt B, Giannarini G, Bortolus R, Rescigno P, Banna GL, Signori A, Obispo MAL, Perris R, Antonelli A. Brunelli M, et al. Among authors: scaltriti m. J Pers Med. 2022 Apr 30;12(5):727. doi: 10.3390/jpm12050727. J Pers Med. 2022. PMID: 35629151 Free PMC article.
The Oncogenic PI3K-Induced Transcriptomic Landscape Reveals Key Functions in Splicing and Gene Expression Regulation.
Ladewig E, Michelini F, Jhaveri K, Castel P, Carmona J, Fairchild L, Zuniga AG, Arruabarrena-Aristorena A, Cocco E, Blawski R, Kittane S, Zhang Y, Sallaku M, Baldino L, Hristidis V, Chandarlapaty S, Abdel-Wahab O, Leslie C, Scaltriti M, Toska E. Ladewig E, et al. Among authors: scaltriti m. Cancer Res. 2022 Jun 15;82(12):2269-2280. doi: 10.1158/0008-5472.CAN-22-0446. Cancer Res. 2022. PMID: 35442400
Author Correction: The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers.
Rosen EY, Won HH, Zheng Y, Cocco E, Selcuklu D, Gong Y, Friedman ND, de Bruijn I, Sumer O, Bielski CM, Savin C, Bourque C, Falcon C, Clarke N, Jing X, Meng F, Zimel C, Shifman S, Kittane S, Wu F, Ladanyi M, Ebata K, Kherani J, Brandhuber BJ, Fagin J, Sherman EJ, Rekhtman N, Berger MF, Scaltriti M, Hyman DM, Taylor BS, Drilon A. Rosen EY, et al. Among authors: scaltriti m. Nat Commun. 2022 Apr 5;13(1):1936. doi: 10.1038/s41467-022-29700-y. Nat Commun. 2022. PMID: 35383193 Free PMC article. No abstract available.
The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers.
Rosen EY, Won HH, Zheng Y, Cocco E, Selcuklu D, Gong Y, Friedman ND, de Bruijn I, Sumer O, Bielski CM, Savin C, Bourque C, Falcon C, Clarke N, Jing X, Meng F, Zimel C, Shifman S, Kittane S, Wu F, Ladanyi M, Ebata K, Kherani J, Brandhuber BJ, Fagin J, Sherman EJ, Rekhtman N, Berger MF, Scaltriti M, Hyman DM, Taylor BS, Drilon A. Rosen EY, et al. Among authors: scaltriti m. Nat Commun. 2022 Mar 18;13(1):1450. doi: 10.1038/s41467-022-28848-x. Nat Commun. 2022. PMID: 35304457 Free PMC article.
MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer.
Prasad M, Zorea J, Jagadeeshan S, Shnerb AB, Mathukkada S, Bouaoud J, Michon L, Novoplansky O, Badarni M, Cohen L, Yegodayev KM, Tzadok S, Rotblat B, Brezina L, Mock A, Karabajakian A, Fayette J, Cohen I, Cooks T, Allon I, Dimitstein O, Joshua B, Kong D, Voronov E, Scaltriti M, Carmi Y, Conde-Lopez C, Hess J, Kurth I, Morris LGT, Saintigny P, Elkabets M. Prasad M, et al. Among authors: scaltriti m. J Immunother Cancer. 2022 Mar;10(3):e003917. doi: 10.1136/jitc-2021-003917. J Immunother Cancer. 2022. PMID: 35292516 Free PMC article.
José Baselga 1959-2021.
Scaltriti M. Scaltriti M. Nat Cancer. 2021 May;2(5):479-480. doi: 10.1038/s43018-021-00209-5. Nat Cancer. 2021. PMID: 35122018 No abstract available.
The present and future of PI3K inhibitors for cancer therapy.
Castel P, Toska E, Engelman JA, Scaltriti M. Castel P, et al. Among authors: scaltriti m. Nat Cancer. 2021 Jun;2(6):587-597. doi: 10.1038/s43018-021-00218-4. Epub 2021 Jun 17. Nat Cancer. 2021. PMID: 35118422 Free PMC article.
Pancreatoblastomas and mixed and pure acinar cell carcinomas share epigenetic signatures distinct from other neoplasms of the pancreas.
Benhamida JK, Vyas M, Tanaka A, Wang L, Bahrami A, Ozcan K, Basturk O, Villafania L, Mata DA, El Jabbour T, Selenica P, Roehrl MHA, Weigelt B, Reis-Filho JS, Scaltriti M, Klimstra DS. Benhamida JK, et al. Among authors: scaltriti m. Mod Pathol. 2022 Jul;35(7):956-961. doi: 10.1038/s41379-021-00989-2. Epub 2021 Dec 30. Mod Pathol. 2022. PMID: 34969956
149 results